Conjugate Vaccine Market Research Report - Global Forecast till 2027

Global Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), By Indication (Influenza, Pneumococcal, Meningococcal, And Others) By End Users (Pediatrics And Adults) - Global Forecast Till 2027

ID: MRFR/Pharma/2981-HCR | February 2021 | Region: Global | 115 pages

Please note that the assessment period of report has been updated from 2023 to 2027. Cordially fill the sample form for updated data.

Synopsis of the Global Conjugate vaccines Market


Market Scenario


Conjugate Vaccines are formed by covalently bonding a weak antigen to the strong antigen. This is done to boost the hosts’ immunological response. The poor antigen is a polysaccharide that is attached to the strong protein antigen. The major drivers for the growth of the global conjugate vaccine market are initiatives taken by the government, advancement in the vaccine formulation, and prevention of major infectious diseases, for instance meningitis and others. Furthermore, increasing investments by the companies in research & development, rising focus on immunization programs, and growing demand for vaccination expected to boost the growth of the market over the review period. Increasing prevalence of infectious diseases in children and rising number of awareness programs to promote vaccination will drive the growth of this market during the forecast period.


The strength or effectiveness of conjugate vaccines needs to improve, which may hamper the growth of the market.


The global conjugate vaccine market is expected to grow at a healthy CAGR of 10.5% during the forecast period 2017-2023.


Key Players in the Global Conjugate vaccines Market 


Some of the key players in this market are GlaxoSmithKline plc. Merck & Co., Inc. (U.S), Fablife. (India), SutroVax Inc.(U.S), Sanofi Pasteur SA.(France), Pfizer (U.S), Sinovac Biotech Ltd. (China), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(U.S).


Intended Audience



  • Research and development (R&D) companies

  • Government and independent research laboratories

  • Government and independent regulatory authorities

  • Academic medical institutes and universities

  • Pharmaceutical industries


Market Segments


The global Conjugate vaccine is segmented on the basis of type, indication, and end users. On the basis type it is segmented into Haemophilus B, monovalent, multivalent, others. On the basis of indication, it is segmented into Influenza, Pneumococcal, Meningococcal, others. On the basis of end users, it is segmented into pediatrics and adults.


FIGURE 1 Global Conjugate Vaccines Market, by Indication, 2016 (%)
Conjugate Vaccines Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the Global Conjugate vaccines Market    


On the regional basis, the market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. America dominates the largest market due to a significant use of the vaccine for preventing diseases and favorable conditions for research and development.


Europe is the second largest Conjugate Vaccines market in the globe followed by Asia Pacific. In Europe availability of funds for research and development activities and growing emphasis on research for prevention measures of diseases is increasing. Whereas, Asia Pacific shows the fastest growth in this market due to the increasing prevalence of communicable diseases. Developing countries in this region are emphasizing research on diseases caused to children’s and preventive measures for treating them. Mainly, India and China are expected to be an emerging and the fastest growing market due to the increasing population and prevalence of diseases.


The Middle East & Africa owns the lowest market in the global conjugate vaccines market due to less availability medical facilities.


Global Conjugate vaccines Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology
Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


 



Frequently Asked Questions (FAQ) :


What would be the CAGR of the Conjugate Vaccine Market during the forecast period of 2018-2023?

The players involved are Merck & Co., Inc. (U.S), GlaxoSmithKline plc., SutroVax Inc. (U.S), Sanofi Pasteur SA. (France), Fablife. (India), Sinovac Biotech Ltd. (China), Pfizer (U.S), Taj Pharmaceuticals Limited (India), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Bavarian Nordic (U.S), and others.

The Americas hold the maximum Conjugate Vaccine Market share and are projected to retain dominance.

The indications are Influenza, Pneumococcal, Meningococcal, and others.

The types are Haemophilus B, monovalent, multivalent, and others in the Conjugate Vaccine Market.

Table of Contents

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6. Global Conjugates Vaccines Market, by Type

6.1 Haemophilus B

6.2 Monovalent

6.3 Multivalent

6.4 Others

7. Global Conjugates Vaccines Market, by Indication

7.1 Influenza

7.2 Pneumococcal

7.3 Meningococcal

7.4 Others

8. Global Conjugates Vaccines Market, by End User

8.1 Pediatrics

8.2 Adults

9. Global Conjugates Vaccines Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 UK

9.3.1.3 France

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Cost of Products

10.2 Production Capacity of Major Players

11 Company Profile

11.1 GlaxoSmithKline plc.

11.1.1 Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Updates

11.1.4 Key Developments

11.2 Merck & Co., Inc.

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Updates

11.2.4 Key Developments

11.3 Fablife

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Updates

11.3.4 Key Development

11.4 Pfizer Inc

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Updates

11.4.4 Key Development

11.5 SutroVax Inc

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Updates

11.5.4 Key Developments

11.6 Taj Pharmaceuticals Limited

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Updates

11.6.4 Key Developments

11.7 Sanofi Pasteur SA

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Updates

11.7.4 Key Developments

11.8 Sinovac Biotech Ltd

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Updates

11.8.4 Key Developments

11.9 Bavarian Nordic

11.9.1 Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financial Updates

11.9.4 Key Developments

11.9 Others

12 Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Conjugates Vaccines Industry

13 Appendix